A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
CompletedOBSERVATIONAL
Enrollment
39,357
Participants
Timeline
Start Date
May 17, 2022
Primary Completion Date
July 29, 2022
Study Completion Date
July 29, 2022
Conditions
Coronary Artery DiseaseAtrial Fibrillation
Trial Locations (1)
55216
Boehringer Ingelheim - International GmbH, Ingelheim
NCT05051904 - A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin | Biotech Hunter | Biotech Hunter